Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 121

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 121
---
Accounts receivable, net(920)(308)Inventory(4,418)(7,353)Prepaid expenses and other current and non-current assets(2,227)(4,863)Accounts payable2,891 7,357 Accrued expenses and other current liabilities(9,644)(9,860)Income taxes payable(871)52,682 Operating lease liabilities(12,473)(11,162)Other non-current liabilities(790)— Net cash used in operating activities(276,764)(256,674)Investing activitiesPurchases of marketable securities(480,681)(1,344,107)Proceeds from maturities and sales of marketable securities780,985 668,248 Payments associated with license agreement(10,000)— Proceeds from sale of contingent payments— 889,136 Proceeds from milestone payment from gain on sale of oncology business— 200,000 Purchases of property and equipment(3,196)(718)Proceeds from sale of equipment— 40 Net cash provided by investing activities287,108 412,599 Financing activitiesNet proceeds from stock option exercises and employee stock purchase plan6,119 9,600 Net cash provided by financing activities6,119 9,600 Net change in cash and cash equivalents16,463 165,525 Cash and cash equivalents at beginning of the period76,247 88,205 Cash and cash equivalents at end of the period$92,710 $253,730 Supplemental disclosure of non-cash investing and financing transactionsAdditions to property and equipment in accounts payable$336 $61 Net cash taxes paid (returned)$1,568 $(637)

See accompanying Notes to Condensed Consolidated Financial Statements.

6

AGIOS PHARMACEUTICALS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Overview and Basis of Presentation

References to AgiosThroughout this Quarterly Report on Form 10-Q, "Agios," "the company," “we,” “us,” and “our,” and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and “our Board of Directors” refers to the board of directors of Agios Pharmaceuticals, Inc.OverviewWe are a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. We champion an inclusive culture that fosters